Next Milestone Ventures
Parkside Scientific
New York City based Parkside Scientific develops novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory disorders.
Parkside Scientific Team:
Gary Duberstein
Next Milestone is a Program of
